• About Us
    Company Profile Growth & Development Mission and Vision Core Team Cooperative Partner Honor Patent
  • Technology
    Labyrinth Next Generation Microfluidic Rare Cell Capture Platform CTC 3D Culture Technology Platform High-Sensitivity CTC Drug Susceptibility Testing Platform
  • Products and Services
    Medical Devices Precision Medical Testing Services Pharmaceutical Services
  • Resources
    Case Study Industry Guide
  • News
    Company News Industry News Publication

Resources

Define new standards for liquid biopsy, empower precision medicine with rare live cell capture

  • Case Study
  • Industry Guide
  • Detection of Minimal Residual Disease (MRD) In Tumor Surgery

    Detection of Minimal Residual Disease (MRD) In Tumor Surgery

    2025-08-02

    In today's increasingly awakened awareness of health, regular physical examinations have become a "mandatory course" for many people to protect their lives. Ms. W, who is 41 years old, is a typical representative among them. She has maintained the habit of regular health consultations for many years.

    Learn More >
  • CTC Drug Sensitivity Test

    CTC Drug Sensitivity Test

    2025-08-02

    Drug sensitivity testing was performed on tumor cells derived from two patients with ovarian malignant germ cell tumors: Case NO.009 (treatment-naïve) and Case NO.015 (relapsed case). The results demonstrated that:

    Learn More >
  • CTC Cell Lines and PDX Model Establishment

    CTC Cell Lines and PDX Model Establishment

    2025-08-02

    This study conducted 3D culture on circulating tumor cell (CTC)-derived cell lines from three pancreatic cancer patients. All cell lines successfully formed spheroid aggregates within 14 days. H&E staining revealed that these spheroids exhibited patient-specific morphological characteristics, consistent with clinical pancreatic cancer tissue histology. Immunophenotyping confirmed their epithelial origin as CK+/CD45-/DAPI+ tumor cells.

    Learn More >
  • Monitoring Treatment Efficacy and Tumor Recurrence/Metastasis

    Monitoring Treatment Efficacy and Tumor Recurrence/Metastasis

    2025-08-02

    CTC Count Dynamics Correlate with Therapeutic Response

    Learn More >
  • ADC Target Detection via CTC Analysis

    ADC Target Detection via CTC Analysis

    2025-08-02

    A Stage II cervical cancer patient provided preoperative peripheral blood samples. The Labyrinth microfluidic platform successfully isolated 303 circulating tumor cells (CTCs), demonstrating:

    Learn More >
  • About Us

    Company Profile Growth & Development Mission and Vision Core Team
  • Cooperative Partner Honor Patent
  • Technology

    Labyrinth Next Generation Microfluidic Rare Cell Capture Platform CTC 3D Culture Technology Platform High-Sensitivity CTC Drug Susceptibility Testing Platform
  • Products and Services

    Medical Devices Precision Medical Testing Services Pharmaceutical Services
  • Resources

    Case Study Industry Guide
  • News

    Company News Industry News Publication
The world's first original high-tech platform dedicated to precision medicine

Service Hotline:0512-66033228

Email:info@labyrinthbiotech.com

Address:5th Floor, Building 2, No. 21 Jingu Road, Suzhou Industrial Park

Copyright © 2016-2024 Racetec. All Rights Reserved.© Suzhou Laibo Ruisi Biotechnology Co., Ltd


Value added Telecommunications Business License: Guangdong B2-20221537